This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Shorting Alexza Pharma On FDA's Adasuve Approval

NEW YORK ( TheStreet) -- A true stock trader is agnostic, freely shifting his position in the same stock, going long or short, sometimes multiple times, whenever the situation warrants. Biotech traders profit most from this flexibility when biotech stock prices "run up" into catalysts and then "run down" after the catalyst passes.

The biotech run down most often occurs following an FDA drug approval. Recent examples include Exelixis (EXEL), Discovery Labs (DSCO - Get Report), Vivus (VVUS), Arena Pharma (ARNA), Talon Therapeutics (TLON) and Horizon Pharma (HZNP - Get Report). All of these stocks trade today at values substantially lower than their respective highs reached during the "run-up" into FDA drug approval. Just last Friday, Ariad Pharmaceuticals (ARIA) received early FDA approval for its leukemia drug and the share price dropped 20%.

Getting a drug approved by the FDA is an amazing achievement, so why do so many biotech and drug stocks fall following this happy event?

The answer, of course, is markets are forward looking, so drug approvals are often baked into stock valuations well before the event takes place. This is particularly true in cases where drug approval is widely expected. When drug approval is actually announced, stocks are already fairly valued. In worst cases, the run-up causes drug-approval stocks to overshoot on valuation. When this happens, profit taking can get manic as traders trip over each other to exit positions as quick as possible.

Alexza Pharmaceuticals (ALXA - Get Report) is setting up nicely for a run-down trade ahead of Friday's FDA approval decision on the company's Adasuve therapy for schizophrenia agitation. I wrote a column on Nov. 20 recommending Alexza as a run-up trade and now it's time to reverse course.

The stock is trading at new highs following this week's decision by European regulators to recommend Adasuve for approval. Run-up traders locked in gains before the European decision was announced and now wait for the FDA to make its ruling known on Dec. 21.

Alexza's stock price is likely to sell off on news of Adasuve's approval by FDA. At these levels, the stock is pricing in FDA approval and unrealistic Adasuve sales. [Zacks analyst Jason Napodano's <a href="" rel="nofollow">take on why Alexza is overvalued</a> is a must read.]

How to profit from the coming Alexza run down: The most common method is to short Alexza shares on the approval spike and cover into the run down. I'd expect to see a price spike in Alexza following the Adasuve approval announcement, followed by multiple days where shares will close lower than they open.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALXA $1.04 0.00%
DSCO $0.28 0.00%
EXEL $5.47 0.00%
HZNP $21.77 0.00%
AAPL $117.81 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs